tioguanine + methotrexate + mercaptopurine

6-tioguanine + standard maintenance therapy is an experimental combination regimen investigated in the Phase 3 TEAM (Thiopurine Enhanced ALL Maintenance) trial, which is a sub-protocol of the ALLTogether1 master protocol. This treatment involves the addition of low-dose oral 6-thioguanine (tioguanine) to the standard maintenance backbone consisting of methotrexate and 6-mercaptopurine. The regimen is specifically designed for patients aged 0–45 years with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia (ALL) who are stratified into the intermediate risk-high (IR-high) group. The primary objective of adding tioguanine is to increase the levels of DNA-incorporated thioguanine nucleotides (DNA-TG), thereby enhancing the cytotoxic effect on leukemic cells and reducing the risk of relapse. The trial is led by the ALLTogether Consortium across multiple European countries.

Brand names

TabloidLanvisPurinetholTrexall

Other names

6-tioguanine + standard maintenance therapy6-thioguanine + standard maintenance6TG + standard maintenanceThiopurine Enhanced ALL Maintenance